Adaptive Biotechnologies ADPT 深 滬
已收盤 02-06 16:00:00 美东时间
15.77
-0.700
-4.25%
華盛通- 最 高17.98
- 今 開17.82
- 成交量 414.03万股
- 最 低 15.065
- 昨 收 16.47
- 總市值 24.08亿
- 52周最高 20.76
- 市盈率 靜 --
- 換手率 2.71%
- 52周最低 6.255
- 委 比 -47.75%
- 總股本 1.53亿
- 歷史最高 71.25
- 量 比 1.91
- 振 幅 17.70%
- 歷史最低 2.28
- 每 手 1
- 風險率 3.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Adaptive Biotechnologies 2025财年Q4营收0.72亿美元，同比增长51.0%；归母净利润亏损0.14亿美元，同比亏损缩窄59.7%
华盛资讯2月6日讯，Adaptive Biotechnologies公布2025财年Q4业绩，公司Q4营收0.72亿美元，同比增长51.0%，归母净利润亏损0.14亿美元，同比亏损缩窄59.7%。
02-06 16:49
Adaptive Biotechnologies shares are trading lower after the company reported Q2 financial results cut its FY26 sales guidance. Also, the company issued Q3 sales guidance below estimates.
Adaptive Biotechnologies shares are trading lower after the company reported Q2...
02-06 05:56
Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q4 financial results.
Adaptive Biotechnologies shares are trading higher after the company reported b...
02-06 05:55
Adaptive Biotechnologies Q4 Earnings Assessment
The Q4 earnings report for Adaptive Biotechnologies (NASDAQ:ADPT) was released ...
02-06 05:08
Chief Scientific Officer Harlan S. Robins Reports Sale of Adaptive Biotechnologies Shares
Chief Scientific Officer Harlan S. Robins Reports Sale of Adaptive Biotechnologies Shares Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This
02-05 08:49
Adaptive Biotechnologies CEO Chad M. Robins Reports Sale of Common Shares
Adaptive Biotechnologies CEO Chad M. Robins Reports Sale of Common Shares Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corporation, has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
02-05 08:37
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Adaptive Biotechnologies Corporation will report its 2025 fourth-quarter and full-year financial results on February 5, 2026, after market close. A conference call with management will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time and can be accessed via the company’s website. The company focuses on using immune system genetics to develop diagnostic and therapeutic products.
01-22 21:05
What's Going On With Adaptive Biotechnologies Shares Tuesday?
Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.
01-13 22:40
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 200 points on M...
01-12 23:07
